| Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer JD Thomas, CG Longen, HM Oyer, N Chen, CM Maher, JM Salvino, ... Cancer research 77 (9), 2439-2452, 2017 | 38 | 2017 |
| Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin-induced diabetic rats using a semiphysiologically based pharmacokinetic model involving … Z Wang, H Yang, J Xu, K Zhao, Y Chen, L Liang, P Li, N Chen, D Geng, ... Drug Metabolism and Disposition 47 (10), 1066-1079, 2019 | 24 | 2019 |
| Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions A Estrada-Bernal, AE Doak, AT Le, H Zhu, N Chen, S Silva Mol Cancer Ther 17, A157, 2018 | 19 | 2018 |
| MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC LC Tyler, AT Le, N Chen, H Nijmeh, L Bao, TR Wilson, D Chen, ... Thoracic Cancer 13 (21), 3032-3041, 2022 | 14 | 2022 |
| Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer JM Salvino, YVV Srikanth, R Lou, HM Oyer, N Chen, FJ Kim Bioorganic & medicinal chemistry letters 27 (10), 2216-2220, 2017 | 7 | 2017 |
| Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC AA Bokhari, WY Lai, AT Le, JL Gabre, TP Chuang, S Fransson, ... Lung Cancer 171, 103-114, 2022 | 3 | 2022 |
| Abstract A29: The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies AT Le, A Estrada-Bernal, L Schubert, A Doak, N Chen, K Davies, ... Clinical Cancer Research 24 (17_Supplement), A29-A29, 2018 | 2 | 2018 |
| MIG6 mediates adaptive and acquired resistance to ALK/ROS1 fusion kinase inhibition through EGFR bypass signaling N Chen, LC Tyler, AT Le, EA Welsh, B Fang, A Elliott, KD Davies, ... Molecular Cancer Therapeutics, OF1-OF14, 2023 | | 2023 |
| Sigma1 Regulates Lipid Droplet–Mediated Redox Homeostasis Required for Prostate Cancer Proliferation HM Oyer, AR Steck, CG Longen, S Venkat, K Bayrak, EB Munger, D Fu, ... Cancer Research Communications 3 (10), 2195-2210, 2023 | | 2023 |
| Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression TL Peters, N Chen, LC Tyler, AT Le, A Dimou, RC Doebele Thoracic Cancer, 2023 | | 2023 |
| miR205 mediates acquired resistance to ALK inhibition via targeting Mig6 expression and enhancing EGFR signaling N Chen, RC Doebele Cancer Research 82 (12_Supplement), 1100-1100, 2022 | | 2022 |
| Abstract P071: Phosphoproteomics identifies Mig6 as a key mediator of adaptive resistance to ALK/ROS1 oncogene inhibition N Chen, AT Le, EA Welsh, B Fang, EB Haura, RC Doebele Molecular Cancer Therapeutics 20 (12_Supplement), P071-P071, 2021 | | 2021 |
| Phosphoproteomic analyses identify EGFR as a critical cooperative kinase for ALK N Chen, AT Le, AE Doak, G Zhang, B Fang, EB Haura, RC Doebele Cancer Research 80 (16_Supplement), 1865-1865, 2020 | | 2020 |
| Small Molecule Sigma1 Modulators Induce the Degradation of Androgen Receptor and Splice Variants in Castration Resistant Prostate Cancer Cells N Chen Drexel University, 2016 | | 2016 |
